{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:06:43Z","timestamp":1782439603177,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":184,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p><jats:bold>Background and Aim:<\/jats:bold> Since 2019, LDL\u2010cholesterol (LDL\u2010C) is the risk factor with the strictest goals and the most difficult to reach, due to its role in the development of atherosclerotic plaque and, therefore, cardiovascular risk. The objective of the TERESA\u2010AP study is to analyze the degree of LDL\u2010C control in patients followed up in primary care with lipid\u2010lowering drug treatment (LLT).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Observational, multicenter, cross\u2010sectional, nationwide study was conducted, in which 50 PC physicians recruited 929 patients who were receiving LLT during at least the preceding 6 months. The variables required to estimate the patients\u2019 cardiovascular risk and LDL control were recorded.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Nearly half of sample was women (50.5%), and the mean age was 67.8 (10.4) years. High blood pressure (65.3%) and sedentary lifestyle (59.7%) were the most frequent risk factors. Recommended goals were reached in 26.0% (95% CI: 23.3%\u201329.0%) of patients, with a slightly higher percentage in patients with cardiovascular disease (CVD) (26.7%), diabetes mellitus (DM) (35.5%), and a lower one in patients with chronic kidney disease (CKD) (12.1%). The most frequent drug treatments were statin monotherapy (69.0%) and statin with ezetimibe combination (27.6%), with moderate\u2010intensity statins being the most commonly used in both groups.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> On average, only a quarter of the patients followed up in PC and who receive drug treatment reach their therapeutic targets. This percentage is slightly higher if the patients have CVD and DM and lower if they have CKD. The most commonly used therapeutic strategy is moderate\u2010intensity statins, both in monotherapy and in combination with ezetimibe.<\/jats:p>","DOI":"10.1155\/2024\/4227941","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T10:48:35Z","timestamp":1720003715000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Achievement of LDL\u2010Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA\u2010AP Study"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-2820","authenticated-orcid":false,"given":"Sergio","family":"Cinza-Sanjurjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-7685","authenticated-orcid":false,"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fierro-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3655-7180","authenticated-orcid":false,"given":"Jose","family":"Polo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-6078","authenticated-orcid":false,"given":"Vicente","family":"Pallar\u00e9s-Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"e_1_2_12_1_2","unstructured":"Statisticals National Health Mortality and its causes 2022 https:\/\/www.ine.es\/uc\/eJSB1WDBi1."},{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.655688"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001031"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_2_12_7_2","volume-title":"Gu\u00eda de diabetes tipo 2 para cl\u00ednicos: Recomendaciones de la redGDPS","author":"Soid\u00e1n J. G.","year":"2018"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2018.11.003"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093187"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2022.2012"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.13186"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36802"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32332-1"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072140"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.05.016"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216377"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2022.02957"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20032388"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2487"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab718"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025813"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd8110146"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027516"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.46201"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.022"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac620"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01545-8"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.1810"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100665"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2024\/4227941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:35:47Z","timestamp":1736174147000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/4227941"}},"subtitle":["LDL\u2010Cholesterol Goals in Primary Care"],"editor":[{"given":"Arquimedes","family":"Gasparotto Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/2024\/4227941"],"URL":"https:\/\/doi.org\/10.1155\/2024\/4227941","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"4227941"}}